加入收藏 | 返回首页 | 关于我们 | 联系我们
  会员 密码:
 
 2015/09/07 Dynamm...
 2014/10/23 Evolution...
 2014/09/23 Transcrip...
 2014/07/14 Genome E...
 2014/05/19 Probing th...
 2014/03/19 Starting S...
 2014/02/18 Glycosyla...
 2013/12/03 Novel Reg...
 2013/10/25 Natural Pr...
 2013/06/28 Biotechno...
 2013/05/20 Correlatio...
 2013/03/18 Exploring...
 2012/12/17 The Evolu...
 2012/12/04 How much...
 2012/11/05 Non-classi...
 2012/09/14 Regulation...
 2012/07/03 Drosophila...
 2011/05/26 Understan...
 2010/9/10 Recent adva...
 2010/8/12 Aids in 2011...
 2010/6/25 Kinetic Mode...
 2010/6/8 How to get...
 2010/6/4 A p53-based...
 2010/3/1 负氢离子的特性...
 2010/1/20 Biocatalysis...
 2010/1/20 Engineering...
 2010/1/6 脂类营养与健康...
学术活动 >>  · 2014/10/23 Evolution...

报告题目: Evolution of Natural Products for Cancer Chemotherapy
报 告 人:Prof. Jürgen Rohr
             Department of Pharmaceutical Sciences, College of Pharmacy,University of Kentucky
报告时间:10月23日 9:30-11:00
报告地点:徐汇校区哲生馆1楼会议室

Abstract:Natural products always had a major impact on drug discover, particularly for clinical cancer chemotherapeutics, which are ~70% natural product derived. Yet, the natural products themselves are often not optimal, due to toxicity, instability or solubility issues. But the modification of natural products, which are usually too complex for a practical total synthesis, requires a fundamental understanding of their biosynthetic pathways, which in turn enables modification strategies based on combinatorial biosynthesis (pathway engineering) or chemo-enzymatic modifications, such as mutasynthesis or chemical derivatizations. The exact sequence of events in biosyntheses of natural products is essential not only to understand and learn from nature’s strategies and tricks to assemble complex natural products, but also for yield optimization of desired natural products, and application of the above mentioned bio-modification strategies. Classical biosynthetic studies including incorporation experiments, crossfeeding experiments, and genetic studies (gene cluster determination and gene inactivation)led to many proposals of biosynthetic pathways, but often just through in silico analyses of the biosynthetic gene clusters. Investigations of the complex biosyntheses of the aureolic acid group and some examples of the angucycline group of anticancer drugs (mithramycin, landomycin, gilvocarcin) revealed that applied classical methodsfailedto delineate the true biosynthetic sequence of events. In order to unambiguously assign enzyme activities, in vitro pathway reconstitution and systematic studies and recombination of its enzyme components (combinatorial biosynthetic enzymology) turned out to be the only way to delineate the complex post-polyketide tailoring steps toward these anticancer natural products. This not only revealed intriguing multifunctional and/or co-dependent enzymes but also allowed to unambiguously assign the involved enzymes, and corrected many of the earlier drawn hypotheses and conclusions.

版权归(C)Wellness Lab﹫实验室所有 | PENGTA 全程技术支持